论文库首页  论文库
 
论文编号:
论文题目: Nurr1-Based Therapies for Parkinson's Disease
英文论文题目: Nurr1-Based Therapies for Parkinson's Disease
第一作者: Dong, J; Li, S; Mo, JL; Cai, HB; Le, WD
英文第一作者: Dong, J; Li, S; Mo, JL; Cai, HB; Le, WD
联系作者: Le, WD (reprint author), Dalian Med Univ, Affiliated Hosp 1, Dalian 116021, Peoples R China.
英文联系作者: Le, WD (reprint author), Dalian Med Univ, Affiliated Hosp 1, Dalian 116021, Peoples R China.
外单位作者单位:
英文外单位作者单位:
发表年度: 2016
卷: 22
期: 5
页码: 351-359
摘要: Previous studies have documented that orphan nuclear receptor Nurr1 (also known as NR4A2) plays important roles in the midbrain dopamine (DA) neuron development, differentiation, and survival. Furthermore, it has been reported that the defects in Nurr1 are associated with Parkinson's disease (PD). Thus, Nurr1 might be a potential therapeutic target for PD. Emerging evidence from in vitro and in vivo studies has recently demonstrated that Nurr1-activating compounds and Nurr1 gene therapy are able not only to enhance DA neurotransmission but also to protect DA neurons from cell injury induced by environmental toxin or microglia-mediated neuroinflammation. Moreover, modulators that interact with Nurr1 or regulate its function, such as retinoid X receptor, cyclic AMP-responsive element-binding protein, glial cell line-derived neurotrophic factor, and Wnt/-catenin pathway, have the potential to enhance the effects of Nurr1-based therapies in PD. This review highlights the recent progress in preclinical studies of Nurr1-based therapies and discusses the outlook of this emerging therapy as a promising new generation of PD medication.
英文摘要: Previous studies have documented that orphan nuclear receptor Nurr1 (also known as NR4A2) plays important roles in the midbrain dopamine (DA) neuron development, differentiation, and survival. Furthermore, it has been reported that the defects in Nurr1 are associated with Parkinson's disease (PD). Thus, Nurr1 might be a potential therapeutic target for PD. Emerging evidence from in vitro and in vivo studies has recently demonstrated that Nurr1-activating compounds and Nurr1 gene therapy are able not only to enhance DA neurotransmission but also to protect DA neurons from cell injury induced by environmental toxin or microglia-mediated neuroinflammation. Moreover, modulators that interact with Nurr1 or regulate its function, such as retinoid X receptor, cyclic AMP-responsive element-binding protein, glial cell line-derived neurotrophic factor, and Wnt/-catenin pathway, have the potential to enhance the effects of Nurr1-based therapies in PD. This review highlights the recent progress in preclinical studies of Nurr1-based therapies and discusses the outlook of this emerging therapy as a promising new generation of PD medication.
刊物名称: CNS NEUROSCIENCE & THERAPEUTICS
英文刊物名称: CNS NEUROSCIENCE & THERAPEUTICS
论文全文:
英文论文全文:
全文链接:
其它备注:
英文其它备注:
学科: Neurosciences; Pharmacology & Pharmacy
英文学科: Neurosciences; Pharmacology & Pharmacy
影响因子: 3.919
第一作者所在部门:
英文第一作者所在部门:
论文出处:
英文论文出处:
论文类别: Article
英文论文类别: Article
参与作者:
英文参与作者:
 
2014 中国科学院上海生命科学研究院 版权所有